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International medical collaborations, previously known as ‘‘medical missionary work,’’ have existed for centuries.
As aptly described by Panosian and Coates,1 historical motivations for this type of outreach included the desire to spread
‘‘religion as well as compassionate care.’’ The term ‘‘medical missionary’’ has endured over the years because of this history,
and is therefore used in this commentary, but it is not intended to carry any paternalistic implications. Today, we see
many programs (although one easily could argue that the supply is nowhere near close to meeting the demand), coordi-
nated by individuals as well as by entire healthcare institutions and schools, that feature students, trainees, nurses, and
physicians from developed areas of the world donating their time, expertise, and resources to medically underserved com-
munities. These programs are mutually beneficial and enlightening.
Medical missionary-based efforts have witnessed a recent increase in activity related to oncology. Global partnerships
in cancer prevention, detection, treatment, and research are expanding in both scope and volume. This growth has been
fueled by strengthened recognition of the following issues:
• The worldwide cancer burden is rising,2,3 and the increasing cancer mortality rates are disproportionately felt in medium-
and low-income countries.4,5 It is projected that cancer incidence and mortality rates will increase by 1% per year.
• Cancer burden varies by geography as well as cultural background, consistent with evidence that risk factors for selected can-
cers include some that are modifiable, such as those related to diet and lifestyle, or exposure to particular infectious or viral
agents.
• Cancer burden varies by race/ethnicity, suggesting that the pathogenesis of some cancers may have hereditary components
associated with ancestral background; international oncology research programs may therefore improve insights related to
hereditary components of some cancers.
• Regardless of cancer etiology, outcome will be completely dependent on access to appropriate diagnosis and treatment.
• As westernized lifestyles and diet are increasingly adopted in underdeveloped countries, the cancer burden associated with
the more industrialized societies (such as breast and colorectal cancer) is also becoming more prominent in the poorer coun-
tries, but with a notable and tragic lag in acquisition of early detection and treatment advances for these cancers. This
results in even larger-magnitude disparities in cancer outcome between affluent and impoverished parts of the world
Disparities in cancer screening, treatment and outcome between different populations have prompted many groups
to provide support to developing countries via medical ‘‘missionary’’ services, as well as the conduct of cancer research and
clinical trials. Launching cancer research programs in collaboration with developing countries has vital importance, but it
requires patience, dedication, and attention to logistic details that do not necessarily arise in the course of oncology investi-
gations based in the United States. This report is therefore designed to provide some guidance to United States-based can-
cer investigators who are interested in pursuing international research partnerships. The steps described are not necessarily
sequential; several are interrelated and may be pursued on a concomitant basis.
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Commentary
Step 1: Establishing Partnerships
Once an investigator has generated his/her research ques-
tions, and it is clear that an international partnership will
be meaningful, the next critical step is to identify the col-
laborating oncology team. This is not at all a trivial point,
as healthcare resources are quite limited in developing
countries, and oncology teams that can spare time as well
as energy for research endeavors are particularly rare.
Extensive time and money can be spent on the partial de-
velopment of collaborations that never come to fruition.
The investigator can more efficiently identify partnerships
that are likely to be durable if he/she starts out by contact-
ing other investigators within the home institution who
have already established international exchange programs.
Expanding on relationships that have already proven to be
successful will strengthen the institution’s comprehensive
international program, and leads to a more efficient
launching of the novel program. The investigator should
look for ongoing student or trainee exchange programs at
her/his institution. These programs and contacts might be
within other medical departments, or they might even be
coordinated by other schools affiliated with the home
institution, such as the international section of the law
school, business school, or humanities program.
If appropriate contacts are unavailable through the
home institution, another strategy is to identify interna-
tional contacts through the published literature. Lead
authors from studies that were based in the country or
region of interest could include potential collaborators
who might welcome partnerships with international
collaborators.
Academic professional societies, such as the Ameri-
can Society of Clinical Oncology (www.asco.org), the So-
ciety of Surgical Oncology (www.surgonc.org), and the
American College of Surgeons (www.facs.org) all have
international components that can serve the dual purpose
of initiating medical missionary as well as collaborative
research programs.
Step 2: Travel Between the International
Collaborative Sites
Travel by the United States-based investigator
The principal investigator should certainly obtain
his own/her own passport. It is useful (and for many coun-
tries mandatory) to obtain a travel visa for the country
with which you are collaborating. Web-based businesses
are available to coordinate the application process, but in-
formation about visa requirements and the application
process can be obtained directly through the US Depart-
ment of State (http://travel.state.gov/). These visas will
facilitate travel for multiple visits over a prespecified time
interval. The application process usually requires payment
of a fee, submission of the applicant’s passport, additional
applicant photographs, anticipated travel information,
and contact information for references in the country that
is being visited. In some countries, the visa is purchased at
the time of arrival in the foreign country, but for other
countries the process may take several weeks and should
therefore be initiated well in advance of the first planned
travel date. After application processing and approval, the
passport will be returned to the applicant with the visa
enclosed.
Safe travel to developing nations requires careful
attention to infectious risks. Appropriate vaccinations or
prophylaxis to protect against malaria, yellow fever, and/
or other parasites/microbes are essential. Many univer-
sities will have specialized clinics established for preparing
staff/employees for international travel. Alternatively,
investigators can obtain relevant information from the
World Health Organization (http://www.who.int/ith/
vaccines/en/) or the Centers for Disease Control (http://
wwwn.cdc.gov/travel/default.aspx).
The investigator must also address communication
efforts and potential language barriers. If English is not
the primary language of the collaborating country, then
the investigator must plan for availability of translators.
Even when English is the primary language, there may be
regional dialects or languages that are more commonly
used by the local community. Personal familiarity with
these dialects is ideal, but if this is not feasible, then the in-
vestigator should attempt to be accompanied by a collabo-
rator who can communicate more readily with the general
population.
Travel within developing countries can also be prob-
lematic and should be addressed in advance of the planned
visit. Taxi services will not necessarily be available, and
reliable, knowledgeable drivers with safe automobiles
should be identified and their services retained before ar-
rival. The medical personnel with whom the investigator
is collaborating may be able to coordinate these services,
or the hotel may be able to assist.
Bringing international collaborators to the
United States
Sponsorship for international research partners to
visit the United States is quite valuable in cementing the
research partnership. These visits allow the international
collaborators to view the research methods and laboratory
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facilities firsthand. They also provide opportunities for
exchange of information and clinical experiences. For
example, international collaborators may find it useful to
attend meetings of the multidisciplinary tumor board, the
clinical research quality assurance committee, or the pro-
tocol review committee. Observations from these meet-
ings frequently provide ideas that can be modified for
incorporation into the clinical practice of the interna-
tional facility.
Step 3: Conduct of International Human
Subjects Research
Conduct of human subjects research involving interna-
tional populations may require sensitivity to special issues
related to the culture and resources of the partnering com-
munities. For example, compensation to participants
within the United States frequently takes the form of a
modest financial payment or voucher to cover time, travel,
and parking expenses. Participants in developing nations
may have a preference for compensation in the form of
meal(s), bottled water, and/or sanitary products, in addi-
tion to monetary compensation.
As in the United States, all human subjects research
will require review and approval by an institutional review
board (IRB) or its equivalent. The local IRB may require
documentation of the international IRB approval before
considering the protocol, or it may grant preliminary ap-
proval that is contingent on obtaining international ap-
proval. The international IRB-equivalent must have a
Federal Wide Assurance number that documents its ad-
herence to conventional rules of human research subjects
protection. All registered Federal Wide Assurance num-
bers, as well as additional information regarding interna-
tional human subjects research, can be obtained through
the Office for Human Research Protections (http://
www.hhs.gov/ohrp/assurances/assurances_index.html).
Another valuable resource to guide investigators
conducting human subjects research is the Fogarty Inter-
national Center (http://www.fic.nih.gov/). The Fogarty
International Center is dedicated to ‘‘advancing the mis-
sion of the National Institutes of Health by supporting
and facilitating global health research conducted by US
and international investigators, building partnerships
between health research institutions in the US and abroad,
and training the next generation of scientists to address
global health needs.’’ It therefore provides information
regarding funding sources and the legalities of conducting
international research.
Step 4: Specimen Acquisition and Transport
Cancer research frequently involves the transport of tissue
specimens from the patient source to the study laboratory,
and international studies are fraught with potential risks
that are necessarily appreciated when human studies
research is conducted within a single American facility.
The climate of some underdeveloped countries may
involve extremes of temperature that can destroy precious
and unique tissue specimens. The power supply of health-
care and laboratory facilities may be unreliable, which can
jeopardize long-term storage of accumulated tissue speci-
mens. Commercial transport businesses and/or customs
agencies may have restrictions on the transport of particu-
lar types of tissues or tissue storage agents (eg, dry ice). All
of these potential barriers to the successful transport of
research specimens should be sorted out before the actual
research is underway.
Investigators seeking to conduct genotyping studies
that involve DNA extraction may find that use of salivary
sources are easier than reliance on blood specimens, and
saliva collection kits (such as Oragene DNA kits, available
via http://www.dnagenotek.com/products_oragene.htm)
are readily available. Tissue specimens can be well pre-
served and easily transported when formalin-fixed and
embedded in paraffin blocks. Laboratory resources within
the collaborating international institution should be eval-
uated in advance, as many underdeveloped countries will
have very limited supplies of the formalin preparations
that are commonly used in the United States, or they may
have a limited supply of the necessary tissue cassettes. The
investigator from the United States must therefore budget
for the expense of all supplies that are necessary for tissue
acquisition. The manpower used to reserve, allocate, and
store the relevant specimens may also be in limited supply,
and support for these services should also be included in
financial planning for the research. An absolutely critical
point that cannot be overemphasized is the finding that
research specimens from international patient populations
(just as within the United States) can only be considered
available for research if the primary, treating healthcare fa-
cility has already accounted for all tissue necessary for
diagnostic and treatment purposes.
Transport of intact, usable specimens can be further
ensured by initial trial run transport of disposable, nonre-
search specimens. For example, the investigator might col-
lect an aliquot of his/her blood or saliva, use the planned
transport mechanism, and then check for feasibility of the
proposed studies on this specimen after it has reached the
United States-based research or laboratory facility. A
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tissue specimen that would otherwise have been discarded
by the international collaborating facility could be used as
a sample for testing the feasibility of transporting and
studying a formalin-fixed, paraffin-embedded specimen.
Specimens that are already sectioned and fixed onto
microscope slides face the obvious risks associated with
the fragility of glass preparations. In addition, if immuno-
histochemical studies are planned on these slides, the in-
vestigator must be sure that the glass slides are of the
sturdy, heat-resistant composition that is commonly used
in developed countries. The pathology laboratories in
many underdeveloped countries may lack routine avail-
ability of immunohistochemistry services, and they there-
fore may not invest in slides that are appropriate for these
types of studies. As noted previously, the expense and
accommodation of these supplies is a burden that must be
borne by the primary investigator.
The Centers for Disease Control can provide per-
mits for research investigators to serve as ‘‘human cou-
riers’’ in transporting tissue/biologic specimens (permits
to ‘‘import or transfer etiological agents or vectors of
human disease’’), and applications can be obtained at
http://www.cdc.gov/od/eaipp/. The advantages of obtain-
ing this type of permit are that the investigator can person-
ally accompany her/his research specimens during travel
by commercial transit such as airlines, and these permits
are accompanied by special labels that can be applied onto
the specimen containers to minimize the risk of damage
during the necessary inspection process related to interna-
tional security programs. The investigator should carefully
review the Centers for Disease Control regulations to
determine whether his/her specimens would be eligible
for and benefit from using this type of permit.
In summary, it is clear that international studies of
cancer will increasingly involve collaboration with under-
developed countries. Hopefully these research partner-
ships will also strengthen communication and
understanding between diverse populations. The success
of these endeavors would also be expected to improve
access to advances in cancer detection and treatment on a
worldwide basis. Opportunities for cultural and academic
exchange function in both directions; Western investiga-
tors and their trainees benefit greatly from their enlighten-
ment regarding the costs and limits of healthcare
resources worldwide, and the collaborating healthcare
providers in underdeveloped countries can gain from the
expertise and resources donated by their research collabo-
rators. This summary is certainly not a comprehensive
text on the conduct of international oncology research.
Rather, the goal is to stress the value of this work and to
provide some basic points of guidance regarding the suc-
cessful initiation of this work.
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